Shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report) fell 0.5% during trading on Monday . The stock traded as low as $1.88 and last traded at $1.95. 9,989 shares traded hands during trading, a decline of 44% from the average session volume of 17,924 shares. The stock had previously closed at $1.96.
Alaunos Therapeutics Stock Up 0.5 %
The stock’s 50 day moving average is $2.19 and its 200 day moving average is $3.52.
About Alaunos Therapeutics
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
Read More
- Five stocks we like better than Alaunos Therapeutics
- What Are Dividend Challengers?
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- How is Compound Interest Calculated?
- 2 Drone Stocks Surging from Increased Media Attention
- How to Effectively Use the MarketBeat Ratings Screener
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
